法隆制药公司筹集了1 000万欧元的可兑换债券,以优惠条件延长现金跑道和支持关键研究。 Faron Pharmaceuticals raised €10 million in convertible bonds with favorable terms to extend cash runway and support key research.

Faron Pharmaceuticals于2025年12月11日向Heights Capital Management管理的实体发行了第二批1000万欧元的可转换债券，债券到期为2028年，利率为7.5%，转换价格为2.42256欧元。 Faron Pharmaceuticals issued a second EUR10 million tranche of convertible bonds on December 11, 2025, to an entity managed by Heights Capital Management, with the bonds due in 2028, a 7.5% interest rate, and a conversion price of EUR 2.42256. 收益将延展现金跑道至Q2 2026,并支持其人力资源MDS研究和战略举措。 Proceeds will extend cash runway into Q2 2026 and support its HR MDS study and strategic initiatives. 该公司说这项交易,包括特别权利在内,由于条件优惠和选择有限,有利于股东。 The company says the deal, including special rights, is shareholder-friendly due to favorable terms and limited alternatives.